| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| TETRAULT LYNN A. | Director | C/O ALUMIS INC., 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO | /s/ Sara Klein, Attorney-in-Fact | 2025-05-23 | 0001645512 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | ALMS | Stock Option (Right to Buy) | May 21, 2025 | Common Stock | 21K | $9.26 | Direct | F1, F2, F3, F4 | ||||||
| holding | ALMS | Stock Option (Right to Buy) | May 21, 2025 | Common Stock | 43.3K | $15.14 | Direct | F1, F3, F4, F5 |
| Id | Content |
|---|---|
| F1 | On February 6, 2025, the Issuer entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with ACELYRIN, Inc., a Delaware corporation ("ACELYRIN"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into ACELYRIN (the "Merger"), with ACELYRIN surviving as a wholly owned subsidiary of Issuer. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of ACELYRIN issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Issuer, par value $0.0001 per share, and cash in lieu of any fractional shares. |
| F2 | Received in the Merger in exchange for an employee stock option to acquire 43,680 shares of ACELYRIN common stock for $4.46 per share. |
| F3 | Stock Option is fully vested and exercisable. |
| F4 | Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Issuer and converted into an option to purchase a number of shares of Issuer Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding ACELYRIN stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. |
| F5 | Received in the Merger in exchange for an employee stock option to acquire 89,955 shares of ACELYRIN common stock for $7.29 per share. |